相关实验视频

Updated: Jul 26, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

通过手术治疗的IIIC1p期宫癌患者的预后分析

Xiang Fan¹, Yifei Wang¹, Ni Yang¹

¹Changzhou Maternal and Child Health Care Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, 213000, Jiangsu, China.

World journal of surgical oncology

|June 21, 2023

概括

经过手术治疗的IIIC1p期子宫癌患者的预后不好. 缺乏辅助疗法,高淋巴结比率 (LNR > 0.3) 和高中性粒细胞-淋巴细胞比率 (NLR > 3.8) 独立预测总体存活率 (OS) 和无病存活率 (DFS) 更差.

科学领域:

妇科瘤学妇科瘤学
手术瘤学手术瘤学
病理学病理学病理学

背景情况:

子宫癌 (CC) 是一种流行的妇科恶性瘤,在IIIC1p阶段的患者手术后预后可变.
确定预后因素对于改善这一患者群体的治疗结果至关重要.

研究的目的:

分析影响IIIC1p阶段宫癌预后的因素. 接受手术治疗的宫癌患者.
确定总生存率 (OS) 和无病生存率 (DFS) 的独立预测因素.

主要方法:

对102名经过手术的IIIC1p期子宫癌患者的回顾性分析.
数据收集包括临床,病理和治疗变量;使用Kaplan-Meier和COX回归的生存分析.
构建了名图来预测OS和DFS,准确度通过Harrell的C指数和校准曲线进行测量.

主要成果:

在该队列中,5年的OS为64.7%,5年的DFS为62.7%.
多变量分析发现没有术后辅助疗法,淋巴结比率 (LNR) >0.3,中性粒细胞-淋巴细胞比率 (NLR) >3.8作为独立的风险因素.
这些因素与较差的OS和DFS有显著的关联.

结论:

经过手术治疗的IIIC1p期子宫癌患者的预后不佳.
没有术后辅助治疗,LNR>0.3和NLR>3.8是减少生存的关键指标.
这些发现突出了风险分层和治疗计划的关键因素.

关键词:

宫癌是发生在宫癌的原因之一.没有疾病的生存率.总体生存率总体生存率预测预后预测预测阶段IIIC1p 阶段IIIC1p

更多相关视频

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment

Published on: December 27, 2024

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...